High Purity New England (HPNE), a leading provider of single-use fluid handling components and solutions, may soon be acquired by Getinge, a global medical technology company. The acquisition is expected to be worth up to $290 million, subject to customary adjustments.
HPNE has been a trusted partner to biopharmaceutical and life science companies for over 20 years, providing high-quality products and services that enable customers to accelerate their research and development efforts. The company’s portfolio includes single-use bags, tubing, connectors, filters, and other components that are critical to the production of biologics and other advanced therapies.
Getinge, on the other hand, is a leading provider of equipment, systems, and solutions for hospitals and life science companies. The company’s products range from surgical tables and lights to sterilization systems and laboratory equipment. With a presence in over 40 countries, Getinge has a strong global footprint and a reputation for innovation and quality.
The acquisition of HPNE would be a strategic move for Getinge, as it would expand the company’s offerings in the life science market. By adding HPNE’s single-use fluid handling components to its portfolio, Getinge would be able to offer a more comprehensive range of solutions to its customers. This would also enable Getinge to better serve the growing demand for single-use technologies in the biopharmaceutical industry.
In addition to expanding its product offerings, the acquisition of HPNE would also give Getinge access to a highly skilled workforce with deep expertise in single-use technologies. HPNE’s team of engineers and scientists have years of experience in designing and manufacturing fluid handling components that meet the rigorous standards of the biopharmaceutical industry. This expertise would be invaluable to Getinge as it seeks to grow its presence in the life science market.
The acquisition of HPNE is subject to regulatory approvals and other customary closing conditions. If completed, it would be a significant milestone for both companies and a testament to the strength of the life science market. With the demand for advanced therapies and biologics continuing to grow, companies like HPNE and Getinge are well-positioned to play a critical role in the development and production of these life-saving treatments.
- SEO Powered Content & PR Distribution. Get Amplified Today.
- Buy and Sell Shares in PRE-IPO Companies with PREIPO®. Access Here.
- PlatoAiStream. Web3 Data Intelligence. Knowledge Amplified. Access Here.
- Source: Plato Data Intelligence.
An Overview of the FDA’s Draft Guidance on Translation of GLP Study Reports in the United States
An Overview of the FDA’s Draft Guidance on Translation of GLP Study Reports in the United States The Food and...